Anthony Bergmann Sells 24,100 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00.

Capricor Therapeutics Stock Down 4.2%

NASDAQ CAPR opened at $23.07 on Thursday. The stock has a market capitalization of $1.34 billion, a P/E ratio of -9.94 and a beta of 0.39. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37. The firm has a 50-day moving average price of $29.35 and a 200 day moving average price of $28.32.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities research analysts expect that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on CAPR shares. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.67.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its stake in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Capricor Therapeutics by 8.4% in the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 3,205 shares during the period. Rhumbline Advisers increased its stake in Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 3,636 shares in the last quarter. Marshall Wace LLP purchased a new position in Capricor Therapeutics in the 2nd quarter valued at approximately $796,000. Finally, Jump Financial LLC raised its holdings in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after purchasing an additional 69,515 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.